24/08/15 15:28 Filed in: Press
The European Commission, within the frames of Horizon 2020-SME-Instrument-Phase 2 (PHC-12), has positively evaluated the project "GLIOMARK" and approved funding of €4.7 million for the next 4 years. Objective of "GLIOMARK" is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer Tomography (SPECT). The project will be coordinated by ConsulTech GmbH (Germany) and implemented in close collaboration with ProActina SA (Greece).